New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 11, 2014
05:13 EDTSNY, MNKDSanofi, MannKind announce global licensing agreement for Afrezza
Sanofi (SNY) and MannKind (MNKD) announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in 1Q15. Under the collaboration and license agreement, Sanofi will be responsible for global commercial, regulatory and development activities. Under a separate supply agreement, MannKind will manufacture Afrezza at its manufacturing facility in Danbury, Connecticut. In addition, the companies are planning to collaborate to expand manufacturing capacity to meet global demand as necessary. Under the terms of the agreement, MannKind will receive an upfront payment of $150M and potential milestone payments of up to $775M. The milestone payments are dependent upon specific regulatory and development targets, as well as sales thresholds. Sanofi and MannKind will share profits and losses on a global basis, with Sanofi retaining 65% and MannKind receiving 35%. Sanofi has agreed to advance to MannKind its share of the collaboration's expenses up to a limit of $175M.
News For SNY;MNKD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 28, 2015
05:30 EDTSNYGenzyme says FDA grants fast track designation for development of GZ/SAR402671
Genzyme, a Sanofi company, announced that the FDA has granted Fast Track designation for the development of GZ/SAR402671, a new investigational oral substrate reduction therapy for the treatment of Fabry disease. FDAs Fast Track Drug Development Program is designed to facilitate frequent interactions with the FDA review team to expedite the clinical development and review of a New Drug Application, or NDA, for medicines with the potential to treat serious or life-threatening conditions and address unmet medical needs for such disease or conditions. It also provides the opportunity to submit sections of an NDA on a rolling basis before a sponsor submits the complete application. Genzyme is currently enrolling patients in its Phase 2a trial of GZ/SAR402671, and plans to enroll nine treatment-nave male adult patients with Fabry disease in this international, multicenter study.
April 27, 2015
12:34 EDTMNKDMannKind to manufacture 12 unit cartridge strength of AFREZZA
Subscribe for More Information
06:19 EDTSNYPharmceutical companies buy drugs and raises prices, WSJ reports
Subscribe for More Information
April 24, 2015
05:47 EDTMNKDStocks with implied volatility movement; EWT MNKD
Subscribe for More Information
April 22, 2015
10:02 EDTSNYOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Alcatel-Lucent (ALU) upgraded on post-merger outlook at Bernstein... Amazon.com (AMZN) upgraded to Buy, price target raised to $450 at Monness Crespi... BNP Paribas (BNPQY) upgraded to Overweight from Equal Weight at Morgan Stanley... Dolby (DLB) upgraded to Overweight from Neutral at JPMorgan... First Defiance (FDEF) upgraded to Outperform from Market Perform at Raymond James... Gran Tierra (GTE) upgraded to Buy from Neutral at Dundee... Grupo Aval (AVAL) upgraded to Buy from Neutral at Goldman... Manhattan Associates (MANH) upgraded to Buy from Hold at Benchmark Co.... Marriott (MAR) upgraded to Buy from Neutral at MKM Partners... Masco (MAS) upgraded to Outperform from Market Perform at FBR Capital... Nokia (NOK) upgraded on post-merger outlook at Bernstein... Packaging Corp. (PKG) upgraded to Buy from Hold at Deutsche Bank... Rayonier (RYN) upgraded to Sector Perform from Underperform at RBC Capital... Rogers Communications (RCI) upgraded to Buy from Neutral at BofA/Merrill... Sanofi (SNY) upgraded to Neutral from Sell at Citigroup... Select Comfort (SCSS) upgraded to Outperform from Neutral at Wedbush... UniCredit (UNCFF) upgraded to Buy from Sell at Berenberg... Zions Bancorp (ZION) upgraded to Outperform from Market Perform at FBR Capital.
07:07 EDTSNYEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
06:52 EDTSNYSanofi upgraded to Neutral from Sell at Citigroup
Subscribe for More Information
05:58 EDTMNKDStocks with implied volatility above IV index mean; MNKD GMCR
Subscribe for More Information
April 21, 2015
09:01 EDTSNYGenzyme initiates Phase 2a trial to evaluate pharmocodynamics of GZ/SAR402671
Subscribe for More Information
06:03 EDTMNKDStocks with implied volatility above IV index mean; MNKD GMCR
Stocks with implied volatility above IV index mean; MannKind (MNKD) 75, Keurig Green Mountain (GMCR) 52 according to iVolatility.
April 20, 2015
09:20 EDTSNYLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
06:06 EDTMNKDStocks with implied volatility above IV index mean; MNKD GMCR
Subscribe for More Information
April 15, 2015
11:56 EDTSNYSanofi initiated with a Buy at Societe Generale
Subscribe for More Information
07:41 EDTSNYEBD Group to hold a forum
ChinaBio Partnering Forum 2015 is being held in Shanghai, China on April 15-16.
05:51 EDTMNKDStocks with implied volatility movement; ZIOP MNKD
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use